Multiple Myeloma Patients With a Long Remission After Autologous Hematopoietic Stem Cell Transplantation

Authors

Oren Pasvolsky
Zhongya Wang
Denái R Milton
Mark R Tanner
Qaiser Bashir
Samer Srour
Neeraj Saini
Paul Lin
Jeremy Ramdial
Yago Nieto
Guilin Tang
Partow Kebriaei
Yosra Aljawai
Hina N Khan
Hans C Lee
Christine Ye
Krina K Patel
Sheeba K Thomas
Robert Z Orlowski
Elizabeth J Shpall
Richard E Champlin
Muzaffar H Qazilbash

Publication Date

5-17-2024

Journal

Blood Cancer Journal

Abstract

Autologous stem cell transplantation (autoHCT) is considered standard of care for newly diagnosed multiple myeloma (MM). Although most patients eventually progress after autoHCT, a small proportion achieve a durable response. In this retrospective study we included 1576 patients, 244 (15%) of whom were long-term responders (LTR), defined as having a progression-free survival (PFS) of ≥8 years after transplant. Patients in the LTR group were younger than the non-LTR group (median age 58.4 vs. 59.5 years; p = 0.012), less likely to have high-risk cytogenetics (4% vs. 14%; p < 0.001), more often had

Keywords

Humans, Multiple Myeloma, Middle Aged, Hematopoietic Stem Cell Transplantation, Male, Female, Transplantation, Autologous, Aged, Retrospective Studies, Adult, Remission Induction, Treatment Outcome

Comments

Supplementary Materials

Data Availability Statement

PMID: 38760362